Literature DB >> 11055596

Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors.

G Grisaru-Soen1, L Lerner-Geva, N Keller, H Berger, J H Passwell, A Barzilai.   

Abstract

OBJECTIVE: To determine the factors predisposing to Pseudomonas aeruginosa bacteremia as well as the prevalence, source of infection, outcome and prognostic factors in pediatric patients.
METHODS: Retrospective review of pediatric patients with P. aeruginosa bacteremia, at a large tertiary care hospital during a 6.5-year period.
RESULTS: Seventy patients with P. aeruginosa bacteremia were identified. The annual rate of P. aeruginosa bacteremia remained unchanged during the study period. Antibiotic susceptibility remained unchanged except for two patients with extensive burns who developed resistant strains. Underlying diseases were malignancy (50%), prematurity (6%), burns (7%) and others (37%). The overall mortality associated with P. aeruginosa bacteremia was 20%. The fatality rate was higher among the young infants (compared with older children) and those who received previous antibiotic therapy (P = 0.02). Mortality rate was higher in nosocomial than in community-acquired infections (25% compared with 11.5%). The mortality rate of low birth weight and burns patients was significantly higher when compared with oncology patients or other patients, 75 and 40% compared with 11 and 19%, P = 0.01. Multiple regression analysis revealed a correlation only between the underlying disease and mortality (P = 0.02). In the oncology patients the only significant risk factor for mortality was absolute neutrophil count < or =0.1 x 10(9)/l (P = 0.06).
CONCLUSION: P. aeruginosa bacteremia, although apparently not increasing in incidence and antibiotic resistance, is still a common serious complication in immunocompromised children with a high mortality rate. We conclude that the underlying disease is the main determinant of the clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055596     DOI: 10.1097/00006454-200010000-00003

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  17 in total

1.  Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa.

Authors:  Pier Giorgio Cojutti; Natalia Maximova; Giulia Schillani; William Hope; Federico Pea
Journal:  J Antimicrob Chemother       Date:  2019-06-01       Impact factor: 5.790

2.  Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.

Authors:  Berthony Deslouches; Kazi Islam; Jodi K Craigo; Shruti M Paranjape; Ronald C Montelaro; Timothy A Mietzner
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.

Authors:  Scott T Micek; Ann E Lloyd; David J Ritchie; Richard M Reichley; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation.

Authors:  Désirée Caselli; Simone Cesaro; Ottavio Ziino; Giulio Zanazzo; Rosaria Manicone; Susanna Livadiotti; Monica Cellini; Stefano Frenos; Giuseppe M Milano; Barbara Cappelli; Maria Licciardello; Chiara Beretta; Maurizio Aricò; Elio Castagnola
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

5.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

6.  Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.

Authors:  H S Cheong; C-I Kang; Y M Wi; K S Ko; D R Chung; N Y Lee; J-H Song; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-25       Impact factor: 3.267

7.  Secular trends in pediatric bloodstream infections over a 20-year period at a tertiary care hospital in Germany.

Authors:  Markus Hufnagel; Anita Burger; Susanne Bartelt; Philipp Henneke; Reinhard Berner
Journal:  Eur J Pediatr       Date:  2008-01-30       Impact factor: 3.183

8.  Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes.

Authors:  Mi Ae Yang; Jina Lee; Eun Hwa Choi; Hoan Jong Lee
Journal:  J Korean Med Sci       Date:  2011-04-21       Impact factor: 2.153

9.  Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease.

Authors:  Chih-Hsien Chuang; Yi-Hsin Wang; Hsin-Ju Chang; Hsiu-Ling Chen; Yhu-Chering Huang; Tzou-Yien Lin; Egon A Ozer; Jonathan P Allen; Alan R Hauser; Cheng-Hsun Chiu
Journal:  Gut       Date:  2013-08-13       Impact factor: 23.059

10.  An usual approach to treatment of a case of multidrug resistance Pseudomonas aeruginosa peritonitis: parenteral and intraperitoneal aminoglycosides and parenteral colistin.

Authors:  Ian May; Maha Abu-Khdeir; Roland Alexander Blackwood
Journal:  Infect Dis Rep       Date:  2012-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.